Pharmaceutical

New Alzheimer’s disease medication approved in Japan

Eisai and BioArctic’s Leqembi is the only approved treatment that slows cognitive and functional decline in adults with Alzheimer’s.

Sep 25, 2023 - 20:00
New Alzheimer’s disease medication approved in Japan
Eisai and BioArctic’s Leqembi is the only approved treatment that slows cognitive and functional decline in adults with Alzheimer’s.
Read the original article

Tags:

Previous Article

Chromosome-scale genome sequence of Suaeda glauca sheds light on salt stress tol...

Next Article

Pierre Fabre announces another partnership to expand oncology R&D

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Sensorion raises $16m for gene therapies to treat deafness

Sensorion raises $16m for gene therapies to treat deafness

Apr 9, 2024

STAT+: What to know about a pivotal FDA hearing on Sarepta’s gene therapy for Duchenne

STAT+: What to know about a pivotal FDA hearing on Sare...

May 9, 2023

Living in disadvantaged neighborhoods linked to higher dementia risk, study finds

Living in disadvantaged neighborhoods linked to higher ...

Jul 20, 2023